Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
Adult patients
CHOP therapy
CYP3A5 polymorphism
Pharmacokinetics
Vincristine (VCR)
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
19
05
2023
accepted:
08
08
2023
medline:
18
9
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
This study aims to clarify the impact of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine (VCR) in adult patients receiving CHOP therapy. Plasma samples were collected immediately after the end of VCR administration and at 1.5, 2.5, 3.5, 5.5, 9.5, 13.5, and 25.5 h after the start of administration. Areas under the plasma concentration-time curves of VCR in the elimination phase (AUC A total of 41 adult patients were enrolled in this study. The median t The CYP3A5*3 polymorphism was found to be an indicator for predicting exposure to VCR in adult patients receiving CHOP therapy. This information may be useful for the individualization of VCR dosages.
Identifiants
pubmed: 37610625
doi: 10.1007/s00280-023-04580-1
pii: 10.1007/s00280-023-04580-1
doi:
Substances chimiques
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
CYP3A5 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP3A
EC 1.14.14.1
Ubiquitin-Protein Ligases
EC 2.3.2.27
Vincristine
5J49Q6B70F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-398Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107. https://doi.org/10.1016/j.neulet.2014.10.014
doi: 10.1016/j.neulet.2014.10.014
pubmed: 25459280
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265. https://doi.org/10.1038/nrc1317
doi: 10.1038/nrc1317
pubmed: 15057285
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. https://doi.org/10.1056/NEJMoa011795
doi: 10.1056/NEJMoa011795
pubmed: 11807147
Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515–2519. https://doi.org/10.1002/1097-0142(19940515)73:10%3c2515::aid-cncr2820731011%3e3.0.co;2-g
doi: 10.1002/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g
pubmed: 8174048
Sethi VS, Jackson DV Jr, White DR, Richards F 2nd, Stuart JJ, Muss HB et al (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41(9 Pt 1):3551–3555
pubmed: 7260915
Igarashi T, Kishi S, Hosono N, Higashi T, Iwao T, Yano R et al (2021) Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma. Cancer Chemother Pharmacol 87(4):501–511. https://doi.org/10.1007/s00280-020-04220-y
doi: 10.1007/s00280-020-04220-y
pubmed: 33416909
Wu CY, Li GT, Chu CC, Guo HL, Fang WR, Li T et al (2023) Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts. Arch Toxicol 97(2):377–392. https://doi.org/10.1007/s00204-022-03418-8
doi: 10.1007/s00204-022-03418-8
pubmed: 36418572
Dennison JB, Renbarger JL, Walterhouse DO, Jones DR, Hall SD (2008) Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit 30(3):357–364. https://doi.org/10.1097/FTD.0b013e31816b92c9
doi: 10.1097/FTD.0b013e31816b92c9
pubmed: 18520608
Song S, Suzuki H, Kawai R, Sugiyama Y (1999) Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27(6):689–694
pubmed: 10348798
Ahmed S, Zhou Z, Zhou J, Chen SQ (2016) Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinform 14(5):298–313. https://doi.org/10.1016/j.gpb.2016.03.008
doi: 10.1016/j.gpb.2016.03.008
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Gene 27(4):383–391. https://doi.org/10.1038/86882
doi: 10.1038/86882
Skiles JL, Chiang C, Li CH, Martin S, Smith EL, Olbara G et al (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26854
doi: 10.1002/pbc.26854
pubmed: 30051647
Guilhaumou R, Solas C, Bourgarel-Rey V, Quaranta S, Rome A, Simon N et al (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68(6):1633–1638. https://doi.org/10.1007/s00280-011-1745-2
doi: 10.1007/s00280-011-1745-2
pubmed: 21968951
Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D et al (2004) Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76(3):220–229. https://doi.org/10.1016/j.clpt.2004.05.007
doi: 10.1016/j.clpt.2004.05.007
pubmed: 15371983
Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K et al (2021) Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy. Sci Rep 11(1):785. https://doi.org/10.1038/s41598-020-80706-2
doi: 10.1038/s41598-020-80706-2
pubmed: 33436910
pmcid: 7803984
Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ (2012) Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 55(4):290–297. https://doi.org/10.1111/j.1439-0507.2011.02158.x
doi: 10.1111/j.1439-0507.2011.02158.x
pubmed: 22126626
Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66(6):589–593. https://doi.org/10.1053/cp.1999.v66.103403001
doi: 10.1053/cp.1999.v66.103403001
pubmed: 10613614
Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3):243–272. https://doi.org/10.1517/phgs.5.3.243.29833
doi: 10.1517/phgs.5.3.243.29833
pubmed: 15102541
Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y et al (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58(6):417–421. https://doi.org/10.1007/s00228-002-0499-5
doi: 10.1007/s00228-002-0499-5
pubmed: 12242601
Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34(8):1317–1327. https://doi.org/10.1124/dmd.106.009902
doi: 10.1124/dmd.106.009902
pubmed: 16679390
Barnett S, Hellmann F, Parke E, Makin G, Tweddle DA, Osborne C et al (2022) Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. Eur J Cancer 164:127–136. https://doi.org/10.1016/j.ejca.2021.09.014
doi: 10.1016/j.ejca.2021.09.014
pubmed: 34657763
pmcid: 8914346
Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, De Lorenzo S et al (2014) Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15(8):1105–1116. https://doi.org/10.2217/pgs.14.68
doi: 10.2217/pgs.14.68
pubmed: 25084203
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 54(7):709–735. https://doi.org/10.1007/s40262-015-0267-1
doi: 10.1007/s40262-015-0267-1
pubmed: 25860377
Shu W, Chen L, Hu X, Zhang M, Chen W, Ma L et al (2017) Cytochrome P450 genetic variations can predict mRNA expression, cyclophosphamide 4-hydroxylation, and treatment outcomes in Chinese patients with Non-Hodgkin’s lymphoma. J Clin Pharmacol 57(7):886–898. https://doi.org/10.1002/jcph.878
doi: 10.1002/jcph.878
pubmed: 28181240
Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361–367. https://doi.org/10.1002/pbc.22845
doi: 10.1002/pbc.22845
pubmed: 21225912